Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Peripheral Neuropathy in MGUS
NCT00588822Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jan 2005
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in peripheral neuropathy, sponsored by Mayo Clinic. Primary endpoint: Neuropathy Impairment Score improvement at 6 months. Started Jan 2005; status: terminated.
02
Drugs
rituximab
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT00588822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588822.